CCM
CRL icon

Coldstream Capital Management’s Charles River Laboratories CRL Stock Holding History

Coldstream Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$440K Buy
1,941
+60
+3% +$10.7K 0.01% 797
2026
Q1 		$324K Sell
1,881
-102
-5% -$18.9K ﹤0.01% 894
2025
Q4 		$396K Buy
1,983
+45
+2% +$8.16K 0.01% 803
2025
Q3 		$303K Buy
1,938
+20
+1% +$3.18K ﹤0.01% 935
2025
Q2 		$291K Buy
1,918
+203
+12% +$27.1K ﹤0.01% 900
2025
Q1 		$258K Buy
1,715
+347
+25% +$58.2K 0.01% 879
2024
Q4 		$253K Sell
1,368
-439
-24% -$84.6K 0.01% 912
2024
Q3 		$356K Sell
1,807
-86
-5% -$17.9K 0.01% 748
2024
Q2 		$391K Sell
1,893
-5
-0.3% -$1.13K 0.01% 655
2024
Q1 		$514K Buy
1,898
+130
+7% +$31K 0.01% 542
2023
Q4 		$418K Buy
+1,768
New +$348K 0.01% 575
2023
Q3 		– Sell
-1,087
Closed -$229K – 809
2023
Q2 		$229K Sell
1,087
-114
-9% -$22.7K 0.01% 731
2023
Q1 		$242K Sell
1,201
-358
-23% -$81.1K 0.01% 710
2022
Q4 		$340K Buy
+1,559
New +$340K 0.01% 561
2022
Q2 		$233K Buy
1,089
+57
+6% +$13.9K 0.01% 671
2022
Q1 		$293K Sell
1,032
-5
-0.5% -$1.54K 0.01% 572
2021
Q4 		$391K Sell
1,037
-42
-4% -$16.3K 0.01% 513
2021
Q3 		$244K Sell
1,079
-48
-4% -$19.9K 0.01% 346
2021
Q2 		$417K Buy
1,127
+49
+5% +$16.4K 0.02% 307
2021
Q1 		$312K Buy
1,078
+14
+1% +$3.89K 0.02% 313
2020
Q4 		$266K Buy
1,064
+12
+1% +$2.86K 0.02% 318
2020
Q3 		$238K Buy
+1,052
New +$218K 0.02% 272

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Coldstream Capital Management's CRL Position: Q2 2026 in Review

Coldstream Capital Management increased its Charles River Laboratories (CRL) stake by 3.2% in Q2 2026, buying an estimated $10.7K and bringing the position to 1,941 shares worth $440K. The position accounts for 0.01% of the portfolio, ranked #797.

Coldstream Capital Management first reported a position in CRL in Q3 2020 and has held it in 22 quarters since. The position peaked at $514K in Q1 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Coldstream Capital Management held 1,941 shares of Charles River Laboratories worth $440K as of Q2 2026.
  • Coldstream Capital Management bought 60 Charles River Laboratories shares in Q2 2026, an estimated $10.7K.
  • Charles River Laboratories made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #797 holding.
  • Coldstream Capital Management first reported a position in Charles River Laboratories in Q3 2020 and has held it in 22 quarters since.
  • Coldstream Capital Management's Charles River Laboratories position peaked at $514K in Q1 2024.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.